PB0451 - Treatment of Venous Thromboembolic Disease During Pregnancy: A Single-Center, Descriptive, Cohort Study

Sunday, June 23, 2024

13:45 – 14:45 ICT

Room: Exhibition Hall

Presenting Author(s)

Jose A. Aguilar

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Ciudad de México, Distrito Federal, Mexico

Co-Author(s)

Marilyn G. Mendoza, MD

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexico City, Distrito Federal, Mexico
Adriana G. Garcia

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexico City, Distrito Federal, Mexico
TM

Tania Marisol Martinez Garcia

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexico City, Distrito Federal, Mexico
Stephania Sandoval Ocampo, Hematologist

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Ciudad de méxico, Mexico City, Mexico
ML

María Graciela Leal Gutiérrez

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexico City, Distrito Federal, Mexico
ES

Emely J. Soriano Mercedes

Hematologist
Unidad de Investigación de Hemostasia Trombosis y Aterogenesis
Ciudad de México, Distrito Federal, Mexico
Andric Cuevas-Juárez, MD

Medical resident on thrombosis and hemostasis
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexico city, Distrito Federal, Mexico
Margarita M. Thomas, MD

Medical Resident on Thrombosis and Hemostasis
1Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexico city, Distrito Federal, Mexico
AM

Abraham S Majluf

Heamatologist head of unidad de investigacion medica en trombosis hemostasia y aterogenesis
Instituto Mexicano del seguro social
Mexico City, Estado de México, Mexico

Background: Introduction. VTD still remains an import cause of morbidity and mortality during pregnancy.

Aims: Aim. To inform about the clinical characteristics and results of the treatment of Mexican women with VTD during pregnancy.

Methods: Methods. Since January 1st, 2008 up to December 31st, 2023, data of pregnant women with objectively confirmed VTD and refereed for diagnosis and treatment at our center were evaluated. From all patients, we recorded information regarding, demographics, risk factors, diagnosis, treatment, and final obstetric outcomes.

Results: Results. During the study period, 702 pregnant women with an episode of VTD were evaluated but complete information was obtained in only 631 patients. All patients had an objectively demonstrated episode of VTD. Main characteristics of the patients are shown in Table 1. A shown, at every trimester of pregnancy, obesity was the most frequent risk factor followed by history of smoking, presence of venous insufficiency, and prolonged immobilization. Almost all VTD risk factors were significantly more frequent when thrombosis complicated the third trimester. Results of treatment are shown in Table 2. During the acute phase of the VTD event, 620 patients (98.2%), were fully treated with a low molecular weight heparin BID at world-wide accepted doses. After 4 weeks of treatment, 622 patients (98.6%), were switched to a thromboprophylactic dose of low molecular weight heparin OD at world-wide accepted dose during the rest of the pregnancy and, at least, during the first four weeks of the puerperium. Regarding the products, neither bleeding events were recorded among alive children nor other complications.

Conclusion(s): Conclusions. In this prospective study of pregnant women with an episode of VTD, we found a positive impact of the anticoagulant treatment with low molecular weight heparins on almost all efficacy variables without significantly increasing the bleeding episodes. No negative effects were observed in the children of the affected women.